These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32574951)
41. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436 [TBL] [Abstract][Full Text] [Related]
42. The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Friedova L; Motyl J; Srpova B; Oechtering J; Barro C; Vodehnalova K; Andelova M; Noskova L; Fialová L; Havrdova EK; Horakova D; Benedict RH; Kuhle J; Uher T Mult Scler Relat Disord; 2020 Nov; 46():102534. PubMed ID: 33032055 [TBL] [Abstract][Full Text] [Related]
43. Are neurofilaments valuable biomarkers for long-term disease prognostication in MS? Khalil M Mult Scler; 2018 Sep; 24(10):1270-1271. PubMed ID: 30066596 [No Abstract] [Full Text] [Related]
44. Multiple sclerosis: Biomarkers and genetic variants reflect disease course in multiple sclerosis. Wood H Nat Rev Neurol; 2016 Oct; 12(10):553. PubMed ID: 27615421 [No Abstract] [Full Text] [Related]
45. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731 [TBL] [Abstract][Full Text] [Related]
46. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113 [TBL] [Abstract][Full Text] [Related]
47. Serum neurofilament light chain in patients with amyotrophic lateral sclerosis. Kawada T Eur J Neurol; 2020 Nov; 27(11):e65. PubMed ID: 32189420 [No Abstract] [Full Text] [Related]
48. Neurofilament light for measuring the treatment efficacy in clinical practice: are we there yet? Novakova L J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1305. PubMed ID: 31611262 [No Abstract] [Full Text] [Related]
49. The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks. Ljubisavljevic S; Stojanovic I; Basic J; Pavlovic DA Neurotox Res; 2016 Oct; 30(3):530-8. PubMed ID: 27295058 [TBL] [Abstract][Full Text] [Related]
50. Vitamin D Smolders J; Mimpen M; Oechtering J; Damoiseaux J; van den Ouweland J; Hupperts R; Kuhle J Acta Neurol Scand; 2020 Jan; 141(1):77-80. PubMed ID: 31657006 [TBL] [Abstract][Full Text] [Related]
52. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430 [TBL] [Abstract][Full Text] [Related]
53. Serum Phosphorylated Neurofilament Heavy Chain Level in Relapsing Remitting Multiple Sclerosis in Correlation to Disease Activity and Disability. Shehab AA; Solima DA; Abdel-Hafeez MA; Mohamed SM Egypt J Immunol; 2019 Jan; 26(1):1-13. PubMed ID: 31332992 [TBL] [Abstract][Full Text] [Related]
54. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388 [TBL] [Abstract][Full Text] [Related]
55. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Quintana E; Coll C; Salavedra-Pont J; Muñoz-San Martín M; Robles-Cedeño R; Tomàs-Roig J; Buxó M; Matute-Blanch C; Villar LM; Montalban X; Comabella M; Perkal H; Gich J; Ramió-Torrentà L Eur J Neurol; 2018 Sep; 25(9):1189-1191. PubMed ID: 29797629 [TBL] [Abstract][Full Text] [Related]
56. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333 [TBL] [Abstract][Full Text] [Related]
57. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906 [TBL] [Abstract][Full Text] [Related]
58. From neurofilament research to multiple sclerosis clinical practice: Where do we stand? Bodini B; Calabresi PA Neurology; 2017 Feb; 88(9):816-817. PubMed ID: 28148634 [No Abstract] [Full Text] [Related]
59. Neurofilaments as biomarkers in multiple sclerosis. Teunissen CE; Khalil M Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131 [TBL] [Abstract][Full Text] [Related]